Australia's Tetratherix rises on nasal delivery deal of GLP-1 in US market

Tetratherix

16/03/2026 24:07

** Shares of Tetratherix TTX.AX rise as much as 21.6% to A$5.060, logging their biggest intraday session

** The clinical products co signs a research & development agreement with health start-up Superpower Health

** Under deal, Superpower to pay TTX license payment of $3 million per year for up to 10 years

** Co adds that Superpower to buy co's platform polymer, branded as STEPP, for nasal delivery of GLP-1s, peptides, and hormones in the U.S. market

** Stock hits its highest level since October 21

** Stock up over 54% this year, including the day's move

 (Reporting by Rajasik Mukherjee in Bengaluru)

 ((Rajasik.Mukherjee@thomsonreuters.com))